Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158521 · ClinicalTrials.gov registry record · Phase 2
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01158521 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 25 participants.
The verdict
NCT01158521, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pazopanib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well pazopanib hydrochloride works when given before surgery in treating patients with kidney cancer.
Interventions
- PROCEDURE therapeutic conventional surgery
- DRUG pazopanib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-06 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01158521
The ClinicalTrials.gov registry entry for NCT01158521 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which therapeutic conventional surgery is the first listed.
NCT01158521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01158521 about?
NCT01158521 is a clinical study titled "Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer". RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pazopanib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is stu...
What is the current status of trial NCT01158521?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2010-06. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01158521?
The interventions under investigation include: therapeutic conventional surgery (PROCEDURE), pazopanib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01158521?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.